The University of Pittsburgh Cancer Institute (UPCI) Investigational Drug Service (IDS) is directed by Brian M. Miller, PharmD who is assisted by Elizabeth A. Paul, RPh and a pharmacy technician, Kristine M. Fischl. In addition, the clinic pharmacy that works in tandem with the IDS has three full-time pharmacy technicians, four full-time pharmacists, and two part-time pharmacists. These individuals also participate in treating patients enrolled in protocol treatments mainly through order-entry, mixing chemotherapy, and dispensing provided oral medication. The IDS oversees all pharmacy procedures and processes at the UPCI central and community clinical sites and the Clinical and Translational Research Center (CTRC) where UPCI sponsored studies are implemented and most Phase I studies take place. The IDS coordinate all pharmacy procedures associated with UPCI drug-related research protocols. The goal of the IDS is to ensure that the procurement, receipt, storage, accountability, preparation, dispensing, labeling, and shipping of investigational drugs are performed in accordance with all state and federal laws, Joint Commission on Accreditation of Healthcare Organizations (JCAHO), and the local IRB approved protocol guidelines. Clinical recommendations for drug therapy, monitoring plans for a regimen, managing adverse events, and dose calculations are made with respect to the treatment of patients. Additional responsibilities of the IDS include reviewing all approved IRB protocols, standard chemotherapy and protocol regimens, supportive care regimens (antiemetics and other premedications), and investigational drug policies and procedures. UPCI's Off-site locations require special efforts to ensure rigorous and successful implementation, coordination, and monitoring clinical protocols. Throughout the entire network of cancer sites, the IDS provides oversight and monitoring for all pharmacy related activities. IDS also implements a quality assurance program, which includes labeling drugs per protocol and placing specific labeling on each medication to ensure proper dispensing, and an education program of pharmacists and/or pharmacy technicians for new protocols and treatments, inventory control, and optimized patient care.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol :
Concha-Benavente, Fernando; Srivastava, Raghvendra M; Trivedi, Sumita et al. (2016) Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 76:1031-43
Posluszny, Donna M; Dew, Mary Amanda; Beckjord, Ellen et al. (2016) Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey. J Health Psychol 21:2357-66
Vyas, Avani R; Moura, Michelle B; Hahm, Eun-Ryeong et al. (2016) Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem 117:2482-95
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Chen, Mingqing; Sun, Fan; Han, Lei et al. (2016) Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 7:33363-73
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2016) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res :
Delgado, Evan; Boisen, Michelle M; Laskey, Robin et al. (2016) High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol 141:348-56
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa et al. (2016) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 22:2855-64
Beumer, Jan H; Ding, Fei; Tawbi, Hussein et al. (2016) Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. J Clin Oncol 34:110-6

Showing the most recent 10 out of 885 publications